SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:d6acc34b-968d-43ce-8e39-993d8259460a"
 

Search: onr:"swepub:oai:lup.lub.lu.se:d6acc34b-968d-43ce-8e39-993d8259460a" > Effect of different...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Reddel, H. K. (author)

Effect of different asthma treatments on risk of cold-related exacerbations

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • 2011-03-15
  • European Respiratory Society (ERS),2011

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:d6acc34b-968d-43ce-8e39-993d8259460a
  • https://lup.lub.lu.se/record/2187023URI
  • https://doi.org/10.1183/09031936.00186510DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Common colds often trigger asthma exacerbations. The present study compared cold-related severe exacerbations during budesonide/formoterol maintenance and reliever therapy, and different regimens of maintenance inhaled corticosteroids (ICS), with or without long-acting beta(2)-agonists (LABA), and with as-needed short-acting beta(2)-agonists (SABA) or LABA. Reported colds and severe exacerbations (defined by oral corticosteroid use and/or hospitalisation/emergency room visit) were assessed for 12,507 patients during 6-12 months of double-blind treatment. Exacerbations occurring <= 14 days after onset of reported colds were analysed by a Poisson model. The incidence of colds was similar across treatments. Asthma symptoms and reliever use increased during colds. Budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36% versus pooled comparators plus SABA (rate ratio (RR) 0.64; p=0.002), and for individual treatment comparisons, by 52% versus the same maintenance dose of ICS/LABA (RR 0.48; p < 0.001); there were nonsignificant reductions versus higher maintenance doses of ICS or ICS/LABA (RR 0.83 and 0.72, respectively). As-needed LABA did not reduce cold-related exacerbations versus as-needed SABA (RR 0.96). Severe cold-related exacerbations were reduced by budesonide/formoterol maintenance and reliever therapy compared with ICS with or without LABA and with as-needed SABA. Subanalyses suggested the importance of the ICS component in reducing cold-related exacerbations. Future studies should document the cause of exacerbations, in order to allow identification of different treatment effects.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Jenkins, C. (author)
  • Quirce, S. (author)
  • Sears, M. R. (author)
  • Bateman, E. D. (author)
  • O'Byrne, P. M. (author)
  • Humbert, M. (author)
  • Buhl, R. (author)
  • Harrison, T. (author)
  • Brusselle, G. G. (author)
  • Thoren, A. (author)
  • Sjobring, U. (author)
  • Peterson, S. (author)
  • Ostlund, O. (author)
  • Eriksson, GöranLund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-geo (author)
  • Lungmedicin, allergologi och palliativ medicinSektion II (creator_code:org_t)

Related titles

  • In:European Respiratory Journal: European Respiratory Society (ERS)38:3, s. 584-5931399-30030903-1936

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view